Medicament for treatment of liver cancer

• US 10,441,577 B2
• Filed: 07/09/2012
• Issued: 10/15/2019
• Est. Priority Date: 07/08/2011
• Status: Active Grant

• Current Assignee: Helmholtz Zentrum Fuer Infektionsforschung
• Original Assignee: Helmholtz Zentrum Fuer Infektionsforschung
• Inventors: Zender, Lars, Rudalska, Ramona, Dauch, Daniel
• Primary Examiner(s): Lundgren, Jeffrey S
• Assistant Examiner(s): Lee, William Y
• Application Number:
  US14/131,059
• Publication Number:
  US 20150079154A1
• Time in Patent Office: 2,654 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/4412 having oxo groups directly attached to the heterocyclic ring
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/444 containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

Claims

1. A pharmaceutical composition comprising Sorafenib and an inhibitor of the activity of Mapk14 for use as a medicament in the treatment or prevention of liver cancer, wherein the inhibitor is selected from the group consisting of Skepinone,

2. The pharmaceutical composition according to claim 1, wherein the inhibitor has an IC50 for Mapk14 of at maximum 30 nM.

3. The pharmaceutical composition according to claim 1, wherein Sorafenib is contained in a formulation for administration separate from a formulation containing the inhibitor of the activity of Mapk14.

4. The pharmaceutical composition according to claim 1, wherein Sorafenib and the inhibitor of the activity of Mapk14 are contained in one composition.

5. A pharmaceutical combination for the treatment of or prevention of liver cancer comprising:

a pharmaceutical formulation comprising an inhibitor of the activity of Mapk14 and a separate pharmaceutical formulation comprising Sorafenib, wherein the inhibitor is selected from the group consisting of Skepinone,

6. The pharmaceutical combination according to claim 5, wherein the pharmaceutical formulation comprising an inhibitor of the activity of Mapk14 is for administration separate from the administration of the pharmaceutical formulation comprising Sorafenib for the treatment or prevention of liver cancer for administration to a patient, wherein the inhibitor is selected from the group consisting of Skepinone,

7. A method for treatment or prevention of liver cancer comprising administration of an inhibitor of the activity of Mapk14 in combination with Sorafenib, wherein the inhibitor is selected from the group consisting of Skepinone,